Diego Issouribehere , Nicolás Enrique , Paulina Finochietto , Juan Ignacio Felice , Carolina Belli , Clara Ventura , Verónica Milesi
{"title":"Human Voltage-Activated H+ Channel is Highly Expressed in Acute Myeloid Leukemia and is Associated With the Blast Differentiated Stage","authors":"Diego Issouribehere , Nicolás Enrique , Paulina Finochietto , Juan Ignacio Felice , Carolina Belli , Clara Ventura , Verónica Milesi","doi":"10.1016/j.arcmed.2025.103221","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In acute myeloid leukemia (AML), hematopoietic precursors of myeloid cells proliferate rapidly but are arrested at an early stage, impeding their maturation and normal function. The human voltage-activated proton channel (hHv1) is a membrane protein with important roles in myeloid phagocytic cells. This work aimed to evaluate the expression of hHv1 channel as a novel biological marker associated with the process of cell differentiation in AML.</div></div><div><h3>Methods</h3><div>In this study, we evaluated the expression of the hHv1, at both mRNA and protein levels in AML.</div></div><div><h3>Results</h3><div>We demonstrated that the expression of hHv1 is upregulated at both mRNA and protein levels in AML. Moreover, our results indicate that hHv1 expression correlates with the degree of monocytic differentiation in AML cells in a pattern similar to that previously reported for NADPH oxidase (NOX2), a relevant cellular structure functionally coupled to the hHv1 channel. However, while increases in NOX2 components have not been associated with improved prognosis or survival, we found that the hHv1 upregulation was associated with better prognosis and survival outcomes.</div></div><div><h3>Conclusions</h3><div>These results suggest that hHv1 may serve as a novel biomarker for favorable prognosis in AML and may represent a promising therapeutic target.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"56 5","pages":"Article 103221"},"PeriodicalIF":4.7000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0188440925000414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
In acute myeloid leukemia (AML), hematopoietic precursors of myeloid cells proliferate rapidly but are arrested at an early stage, impeding their maturation and normal function. The human voltage-activated proton channel (hHv1) is a membrane protein with important roles in myeloid phagocytic cells. This work aimed to evaluate the expression of hHv1 channel as a novel biological marker associated with the process of cell differentiation in AML.
Methods
In this study, we evaluated the expression of the hHv1, at both mRNA and protein levels in AML.
Results
We demonstrated that the expression of hHv1 is upregulated at both mRNA and protein levels in AML. Moreover, our results indicate that hHv1 expression correlates with the degree of monocytic differentiation in AML cells in a pattern similar to that previously reported for NADPH oxidase (NOX2), a relevant cellular structure functionally coupled to the hHv1 channel. However, while increases in NOX2 components have not been associated with improved prognosis or survival, we found that the hHv1 upregulation was associated with better prognosis and survival outcomes.
Conclusions
These results suggest that hHv1 may serve as a novel biomarker for favorable prognosis in AML and may represent a promising therapeutic target.
期刊介绍:
Archives of Medical Research serves as a platform for publishing original peer-reviewed medical research, aiming to bridge gaps created by medical specialization. The journal covers three main categories - biomedical, clinical, and epidemiological contributions, along with review articles and preliminary communications. With an international scope, it presents the study of diseases from diverse perspectives, offering the medical community original investigations ranging from molecular biology to clinical epidemiology in a single publication.